Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* A two-year open-label study

International Journal of Dermatology

Volumn 51, Issue 1, 2012, Pages 104-110

  Mandelin, Johanna M ^a   Rubins, Andris ^b   Remitz, Anita ^a   Cirule, Kristine ^b   Dickinson, James ^c   Ho, Vincent ^d   Mäkelä, Mika J ^a   Rubins, Silvestrs ^b   Reitamo, Sakari ^a   Undre, Nasrullah ^e  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Latvian Dermatological Institute   (Latvia)

^c Astellas Pharma Global Development   (Netherlands)

^d Skin Care Centre   (Canada)

^e ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; TACROLIMUS;

ALLERGIC RHINITIS; ANAPHYLAXIS; APPLICATION SITE INFECTION; APPLICATION SITE PRURITUS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BRONCHITIS; BRONCHUS OBSTRUCTION; CHICKENPOX; CLINICAL ARTICLE; CONJUNCTIVITIS; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EAR INFECTION; FEMALE; FEVER; GASTROENTERITIS; HUMAN; INFANT; INFLUENZA; KAPOSI VARICELLIFORM ERUPTION; MALE; MECKEL DIVERTICULUM; MULTICENTER STUDY; OINTMENT; OTITIS MEDIA; PHASE 2 CLINICAL TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SKIN INFECTION; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; VIRUS INFECTION;

DERMATITIS, ATOPIC; ECZEMA; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; OINTMENTS; TACROLIMUS; TREATMENT OUTCOME;

EID: 84155163127     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.05015.x     Document Type: Article

References (16)

1. Illi S, von ME, Lau S, et al. The natural course of atopic dermatitis from birth to age 7years and the association with asthma. J Allergy Clin Immunol 2004; 113: 925-931.
2. Wadonda-Kabondo N, Sterne JA, Golding J, et al. A prospective study of the prevalence and incidence of atopic dermatitis in children aged 0-42months. Br J Dermatol 2003; 149: 1023-1028.
3. Furue M, Terao H, Rikihisa W, et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 2003; 148: 128-133.
4. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931-936.
5. Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004; 150: 554-562.
6. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102: 637-644.
7. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: S58-S64.
8. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004; 51: 515-525.
9. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44: S47-S57.
10. Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539-546.
11. Thaçi D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008; 159: 1348-1356.
12. Astellas Pharma GmbH. Summaries of Product Characteristics. Protopic 0.03% Ointment and Protopic 0.1% Ointment. Munich, Germany: Astellas Pharma GmbH, 2009.
13. Reitamo S, Mandelin J, Rubins A, et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. Int J Dermatol 2009; 48: 348-355.
14. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005; 124: 695-699.
15. Rubins A, Gutmane R, Valdmane N, et al. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J Invest Dermatol 2005; 125: 68-71.
16. Krueger GG, Eichenfield L, Goodman JJ, et al. Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis. J Drugs Dermatol 2007; 6: 185-193.